• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Start-Up Stadium Wednesday Morning

Wednesday, June 05, 2024
5B
Start-Up Stadium is designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology partnering event. During the 2024 BIO International Convention select finalists from around the world will share a quick pitch showcasing new technologies and therapeutic solutions to a panel of investor judges, followed by live feedback. This year will also feature evaluation of the presentations from seed-stage company finalists (less than $1M raised) separate from emerging company finalists (more than $1M but less than $10M raised to date). with a winner identified for each category. Past prizes have included 'fast-track' admission review to incubator programs at the Illumina Accelerator and The Innovation Space, as well as complimentary, one-year memberships in the Biotechnology Innovation Organization with access to the cost-savings programs of BIO Business Solutions.
Loading
11:00 AM – 1:00 PM
(PST)
  1. Aluda was founded to reexamine how fundamental cell processes are altered by disease, combining rational drug design with holistic objectives to make wider impact.
    SUS
    • Immunology
  2. Coastar Therapeutics is a venture-backed biotech company based in San Diego, CA focused on next generation gene delivery technology.
    SUS
    • Cell and Gene Therapy and Genome Editing
  3. CytoArm focuses on untreatable diseases through a next generation T cell therapy, Armed-T cell.
    SUS
    • Oncology
  4. Fzata (fzata.com) has solved the oral biologics problem with the BIoPYM platform.
    SUS
    • Platform for Therapeutics
  5. ImmunoShield Therapeutics seeks to enable the high-throughput biomanufacturing of hydrogel-based regenerative medicine products and the application of allogeneic cell products in the absence of chronic systemic immunosuppression.
    SUS
    • Cell and Gene Therapy and Genome Editing
  6. Isosterix is developing a differentiated small-molecule inhibitor of Kat6A, an epigenetic oncogene which is amplified and implicated in multiple tumor types, including breast cancer.
    SUS
    • Oncology
  7. Minutia is developing a regenerative medicine platform that improves safety and success outcomes of transplanted cells, our first therapy is a functional cure for Type 1 and Insulin Dependent Type 2 Diabetes with a simple outpatient procedure.
    SUS
    • Cell and Gene Therapy and Genome Editing
  8. NemaGen Discoveries is a New Jersey-based biotechnology company that is advancing therapies for patients suffering from allergic disorders and pulmonary fibrosis.
    SUS
    • Immunology

 
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS